RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
  Anaemia
  Hemophilia
  Polycythemia
  Thalassemias
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Haematology Channel

subscribe to Haematology newsletter
Latest Research : Haematology

   EMAIL   |   PRINT
New research links αIIbβ3 to Glanzmann thrombasthenia

Apr 20, 2006 - 5:02:00 PM , Reviewed by: Priya Saxena
Together, the two proteins — αIIb and β3 — create a cellular receptor that’s involved in aggregating blood cells for coagulation; analyzing patients with the disorder previously led Coller to develop a novel therapy for heart-attack and stroke victims that targets this receptor.

 
[RxPG] Studying receptors on the surface of blood platelets, sticky cells that cause blood to clot, has given one Rockefeller researcher new insight into potential causes and treatments for certain cardiovascular diseases. Barry Coller, David Rockefeller Professor and the university’s physician-in-chief, has been focusing on a rare disorder known as Glanzmann thrombasthenia, in which platelets lack one of two proteins. Together, the two proteins — αIIb and β3 — create a cellular receptor that’s involved in aggregating blood cells for coagulation; analyzing patients with the disorder previously led Coller to develop a novel therapy for heart-attack and stroke victims that targets this receptor.

In research published in the April 1 issue of Blood, Coller and Beau Mitchell, a research associate in Coller’s lab, further characterize the αIIbβ3 receptor by exploring its production and degradation. With colleagues at the Mount Sinai School of Medicine, they found that the production of the receptor, the protein complex of both αIIb and β3, is dependent on a third molecule called calnexin. Calnexin plays an important role in protein folding, and the researchers found that it not only helps form the αIIbβ3 receptor complex, but also tags improperly folded β3 proteins for destruction. Their findings suggest that the factor that controls receptor formation is likely the calnexin cycle; if the two receptor proteins fail to form a correctly folded complex, αIIb is broken down by the cell. Coller hopes that further study of αIIbβ3 will yield more information about not just Glanzmann thrombasthenia but the synthesis of other receptors like it. These receptors, which are in the integrin superfamily, play a role in many different functions, including embryonic development, inflammation, and tumor growth and metastases, Coller says. “Insights into rare diseases allow us to study and devise strategies for common diseases.”



Publication: April 1 issue of Blood
On the web: Blood 107(7): 2713-2719 (April 1, 2006)  

Advertise in this space for $10 per month. Contact us today.


Related Haematology News
Chromosome 21 abnormality tells oncologists to treat pediatric ALL more aggressively
Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award
Dr. John Eng to receive Golden Goose Award
Could sleeping stem cells hold key to treatment of aggressive blood cancer?
Stem cells enable personalised treatment for bleeding disorder
Treatment with clot-busting drug yields better results after stroke than supportive therapy alone
1 of the key circuits in regulating genes involved in producing blood stem cells is deciphered
Blood test predicts breast cancer recurrence
More than a third of high-risk leukemia patients respond to an experimental new drug
Pre-clinical data shows Angiocidin effective against leukemia

Subscribe to Haematology Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)